Chief Executive Officer
Karen Van Rassel (Canada)

Board of Directors
Susan Thornton, Chair (USA)
Rosmarie Pfau, Vice Chair (Switzerland)
Guy Bouguet, Treasurer (France)
Dr. Serper Diler, Secretary (Turkey)
Maja Kocić, Director (Serbia)
Monica Pasqualin, Director (Brazil)
Lauren Pretorius, Director (South Africa)

Medical Advisory Board
Dr. Laurie Sehn, MD, MPH - Chair (Canada)
Dr. Andreas Engert, MD (Germany)
Dr. John G. Gribben, MD, DSc (England)
Dr. Gilles Salles, MD (France)
Dr. John Seymour, MD (Australia)
Dr. Julie Vose, MD (USA)

Registered Office Address
8 Stavebank Road, North, #401
Mississauga ON Canada
L5G 2T4
+1.905.990.0609

Auditor
MNP
Mr. Joe Bates
50 Burnhamthorpe Road West
Mississauga, ON Canada
L5B 3C2
WHO WE ARE

LC, a worldwide network of lymphoma patient groups, was formed in 2002 and incorporated as a not for profit organisation in 2010. Its express purpose is to create a level playing field of information around the world and to facilitate a community of lymphoma patient organisations to support one another’s efforts in helping patients with lymphoma receive the best care and support.

The need for a central hub of consistent as well as reliable current information was recognised as well as the need for lymphoma patient organisations to share resources, best practices, and policies and procedures. With this in mind, four lymphoma organisations started the LC. Today, there are 75 member organisations from 50 countries.

LC Vision
To free the world of lymphomas.

LC Mission is to:
• Be the global source for lymphoma facts and statistics
• Improve awareness and understanding of lymphomas
• Build capacity for new and existing lymphoma groups.

LC’S VALUE & TONE

LC's values provide organisational direction:
✓ Integrity
✓ Credible
✓ Principled
✓ Impactful
✓ Collaborative
✓ Global/Local
FROM THE CHAIR OF THE BOARD
SUSAN THORNTON

Thank you to the lymphoma community, volunteers, healthcare professionals, researchers, Lymphoma Coalition (LC) members, fellow Board Members and the LC team for all the hard work to bring support and a level playing field of information to lymphoma patients around the world.

Fiscal 2018 was mid point for the three-year plan and we have been able to achieve all that we set out to accomplish.

The know your subtype campaign continued through social media and awareness activities driving home the message that NHL is not a disease. Many members have removed NHL from their literature, their organisation name and encouraging the medical professionals and industry to take it out of their language all together.

Subtype education continued with 11 reports available incorporating biology, access and the patient perspective to bring a picture and understanding of each of these subtypes.

LC provided reports by region as well as the global report on lymphomas to bring attention to the discrepancies of care, advocacy accomplishments by country to gain access to care as well as providing a snapshot of the patient experience.

Data gathering is a big part of what LC does through its Library Resource that holds 2500+ pieces of lymphoma articles and news; the Global Database platform developed as a tool to understand what treatment and clinical trial access is available by country, subtype and line of therapy. Additionally, every two years we gather information on the patient experience through the lymphoma Global Patient Survey (GPS). 6,600 responses were available upon fiscal year end for 2018.

**Lymphoma Coalition Europe**, is a branch of the LC registered in France under the laws following the requirements in France.

Audit and banking procedures are carried out in Canada under the Canadian law. LCE holds a separate on-line euro bank account with Royal Bank of Canada (same bank as Canadian account) through the international branch and pays for LCE expenses from this account.

The LC bookkeeper reconciles the account activity and reports monthly to the Treasurer who in turn, can report a separate LC and LCE report and a combined monthly financial report to the Board. The yearly audit was completed by MNP, Mr. Joe Bates. LCE Regional Director is responsible for raising funds for LCE expenses. Please see the expense charts and the sponsorship charts that follow.

Please visit the LC/LCE website to review the activities, programs and accomplishments to date.

We thank you for your commitment to excellence in patient care. We look forward to continuing as a strong global body striving to provide the best patient care by creating a level playing field of information.

Sincerely,

Susan Thornton
LC GLOBAL SPONSORSHIP HISTORY

LC OPERATING EXPENSES BY CATEGORY
Year ended March 31, 2018
LCE SPONSORSHIP HISTORY

Year ended March 31, 2018

LCE OPERATING EXPENSES BY CATEGORY

Year ended March 31, 2018
Independent Auditors’ Report

To the Members of Lymphoma Coalition:

We have audited the accompanying financial statements of Lymphoma Coalition, which comprise the statement of financial position as at March 31, 2018, and the statements of operations, changes in net assets and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management’s Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the financial statements present fairly, in all material respects, the financial position of Lymphoma Coalition as at March 31, 2018 and the results of its operations, changes in net assets and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Emphasis of Matter
The financial statements of Lymphoma Coalition for the year ended March 31, 2017 have been neither audited nor reviewed.

Additionally, we draw attention to Note 3 to the financial statements which describes the correction of an accounting error. This correction has been applied retrospectively, impacting some comparative amounts for the prior period presented.

Mississauga, Ontario

June 26, 2018

MNP LLP
Chartered Professional Accountants
Licensed Public Accountants
<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>1,285,064</td>
<td>918,382</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>233,218</td>
<td>487,478</td>
</tr>
<tr>
<td>Prepaid expenses and deposits</td>
<td>82,796</td>
<td>4,375</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1,601,078</td>
<td>1,410,235</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>99,164</td>
<td>93,099</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>43,145</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>142,309</td>
<td>93,099</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td>1,458,769</td>
<td>1,317,136</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1,601,078</td>
<td>1,410,235</td>
</tr>
</tbody>
</table>

Approved on behalf of the Board

The accompanying notes are an integral part of these financial statements
# Lymphoma Coalition
## Statement of Operations and Changes in Net Assets

*For the year ended March 31, 2018*

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>1,365,139</td>
<td>1,981,078</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphoma elInformation Project</td>
<td>315,010</td>
<td>431,247</td>
</tr>
<tr>
<td>Members Annual Meeting</td>
<td>246,705</td>
<td>181,383</td>
</tr>
<tr>
<td>Programs</td>
<td>201,584</td>
<td>93,617</td>
</tr>
<tr>
<td>Finance</td>
<td>132,505</td>
<td>64,002</td>
</tr>
<tr>
<td>Lymphoma Coalition Europe</td>
<td>109,200</td>
<td>185,707</td>
</tr>
<tr>
<td>Website Services</td>
<td>64,528</td>
<td>25,956</td>
</tr>
<tr>
<td>Knowledge Exchange</td>
<td>61,929</td>
<td>20,243</td>
</tr>
<tr>
<td>Operations</td>
<td>53,227</td>
<td>51,134</td>
</tr>
<tr>
<td>Alliances</td>
<td>38,818</td>
<td>22,558</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>1,223,506</td>
<td>1,075,877</td>
</tr>
<tr>
<td><strong>Excess of revenue over expenses</strong></td>
<td>141,633</td>
<td>905,201</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>1,317,136</td>
<td>411,935</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>1,458,769</td>
<td>1,317,136</td>
</tr>
</tbody>
</table>

*The accompanying notes are an integral part of these financial statements*
<table>
<thead>
<tr>
<th>Cash provided by (used for) the following activities</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excess of revenue over expenses</td>
<td>141,633</td>
<td>905,201</td>
</tr>
<tr>
<td>Changes in working capital accounts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>254,259</td>
<td>(442,778)</td>
</tr>
<tr>
<td>Prepaid expenses and deposits</td>
<td>(78,421)</td>
<td>20</td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>6,066</td>
<td>(2,009)</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>43,145</td>
<td>-</td>
</tr>
<tr>
<td><strong>Increase in cash</strong></td>
<td>366,682</td>
<td>460,434</td>
</tr>
<tr>
<td><strong>Cash, beginning of year</strong></td>
<td>918,382</td>
<td>457,948</td>
</tr>
<tr>
<td><strong>Cash, end of year</strong></td>
<td>1,285,064</td>
<td>918,382</td>
</tr>
</tbody>
</table>

*The accompanying notes are an integral part of these financial statements*
1. Incorporation and nature of the organization

Lymphoma Coalition (the “Organization”) was incorporated on June 11, 2010, without share capital, by Letters Patent under the Canada Corporations Act and continued under the Canada Not-for-Profit Corporation Act effective January 8, 2015. The Organization is registered as a not-for-profit organization under the provisions of the Income Tax Act (Canada) and is not subject to income taxes.

The Organization’s purpose is to be the global source for lymphoma facts and statistics, improve awareness of lymphomas, and to build capacity for new and existing lymphoma groups.

2. Significant accounting policies

The financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations set out in Part III of the CPA Canada Handbook - Accounting, as issued by the Accounting Standards Board in Canada and include the following significant accounting policies:

Revenue recognition

The Organization follows the deferral method of accounting for contributions. Restricted contributions are recognized as revenue in the year in which the related expenses are incurred.

Unrestricted contributions are recognized as revenue in the year received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Sponsorship revenue is recognized as revenue when the event occurs and the amount to be received can be reasonably estimated and collection is reasonably assured.

Contributed services

Contributed services are recognized both as contributions and expenses in the statement of operations when a fair value can be reasonably estimated and when the services are used in the normal course of the Organization’s operations and would otherwise have been purchased.

Volunteers contribute time and services to assist the organization in achieving its mandate. Due to the difficulty in determining the fair value of these services, these contributions are not recognized in the financial statements.

Financial instruments

The Organization recognizes its financial instruments when the Organization becomes party to the contractual provisions of the financial instrument. All financial instruments are initially recorded at their fair value, including financial assets and liabilities originated and issued in a related party transaction with management. Financial assets and liabilities originated and issued in all other related party transactions are initially measured at their carrying or exchange amount in accordance with Section 3940 Related Party Transactions.

At initial recognition, the Organization may irrevocably elect to subsequently measure any financial instrument at fair value. The Organization has not made such an election.

The Organization measures all of its financial instruments at amortized cost.

Financial asset impairment

The Organization assesses impairment of all of its financial assets measured at cost or amortized cost. When there is an indication of impairment, the Organization determines whether it has resulted in a significant adverse change in the expected timing or amount of future cash flows during the year. If so, the Organization reduces the carrying amount of any impaired financial assets to the highest of: the present value of cash flows expected to be generated by holding the assets; the amount that could be realized by selling the assets; and the amount expected to be realized by exercising any rights to collateral held against those assets. Any impairment, which is not considered temporary, is included in current year excess of revenues over expenses.
2. Significant accounting policies (Continued from previous page)

Financial asset impairment (Continued from previous page)

The Organization reverses impairment losses on financial assets when there is a decrease in impairment and the decrease can be objectively related to an event occurring after the impairment loss was recognized. The amount of the reversal is recognized in the excess of revenue over expenditures in the year the reversal occurs.

Use of estimates

The preparation of financial statements in conformity with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.

Accounts receivable are stated after evaluation as to their collectability and an appropriate allowance for doubtful accounts is provided where considered necessary.

These estimates and assumptions are reviewed periodically and, as adjustments become necessary they are reported in excess of revenues and expenses in the periods in which they become known.

Foreign currency translation

These financial statements have been presented in Canadian dollars, the principal currency of the Organization's operations.

Transaction amounts denominated in foreign currencies are translated into their Canadian dollar equivalents at exchange rates prevailing at the transaction dates. Carrying values of monetary assets and monetary liabilities reflect the exchange rates at the statement of financial position date. Gains and losses on translation or settlement are included in the determination of excess of revenue over expenses for the current period.

3. Correction of an error

During the year, the Organization determined that prior year revenue related to sponsorships was understated by $83,741 compared to amounts previously reported. The retroactive application of this correction increased revenue and excess of revenue over expenses for the year ended March 31, 2017 and accounts receivable and net assets as at March 31, 2017 by $83,741.

4. Commitments

The Organization entered into a five year lease with respect to its premises in September 2015. The lease contains renewal options and future minimum lease payments with estimated minimum annual payments as follows:

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>34,171</td>
</tr>
<tr>
<td>2020</td>
<td>35,257</td>
</tr>
<tr>
<td>2021</td>
<td>16,628</td>
</tr>
<tr>
<td>Total</td>
<td>86,056</td>
</tr>
</tbody>
</table>

5. Financial instruments

The Organization, as part of its operations, carries a number of financial instruments. It is management's opinion that the Organization is not exposed to significant interest, currency, credit, liquidity or other price risks arising from these financial instruments except as otherwise disclosed.

Liquidity risk

Liquidity risk is the risk that the Organization will encounter difficulty in meeting obligations associated with financial liabilities. The Organization's exposure to liquidity risk is mainly in respect of its receipt of funds from its funders and accounts payable and accrued liabilities.
5. **Financial instruments (Continued from previous page)**

**Interest rate risk**

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. Changes in market interest rates may have an effect on the cash flows associated with some financial assets and liabilities, known as cash flow risk, and on the fair value of other financial assets or liabilities, known as price risk.

The Organization is exposed to interest rate cash flow risk related to earnings on excess cash balances.

**Foreign currency risk**

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Organization is exposed to foreign currency risk on cash, accounts receivable and accounts payable held in U.S. dollars and Euro’s. The Organization does not use derivative instruments to reduce its exposure to foreign currency risk. The Canadian dollar equivalent of balances held in foreign currency are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2018 CAD$</th>
<th>2017 CAD$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash - Euro</td>
<td>384,428</td>
<td>106,788</td>
</tr>
<tr>
<td>Accounts receivable - US Dollar</td>
<td>233,218</td>
<td>333,140</td>
</tr>
<tr>
<td>Accounts receivable - Euro</td>
<td>-</td>
<td>35,440</td>
</tr>
<tr>
<td>Accounts payable - Euro</td>
<td>25,597</td>
<td>19,472</td>
</tr>
<tr>
<td><strong>Total foreign currency</strong></td>
<td><strong>643,243</strong></td>
<td><strong>494,840</strong></td>
</tr>
</tbody>
</table>

6. **Comparative figures**

Certain comparative figures have been reclassified to conform with current year presentation.
Recognise World Lymphoma Awareness Day on 15 September!